EP3263584A4 - Auf autophagische zellen gerichtete peptide und verwendung davon - Google Patents
Auf autophagische zellen gerichtete peptide und verwendung davon Download PDFInfo
- Publication number
- EP3263584A4 EP3263584A4 EP16755929.3A EP16755929A EP3263584A4 EP 3263584 A4 EP3263584 A4 EP 3263584A4 EP 16755929 A EP16755929 A EP 16755929A EP 3263584 A4 EP3263584 A4 EP 3263584A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- targeting
- peptide
- autophagic cells
- autophagic
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150028567 | 2015-02-27 | ||
PCT/KR2016/001943 WO2016137279A1 (ko) | 2015-02-27 | 2016-02-26 | 오토파지 세포 표적용 펩타이드 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3263584A1 EP3263584A1 (de) | 2018-01-03 |
EP3263584A4 true EP3263584A4 (de) | 2018-07-25 |
Family
ID=56788865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16755929.3A Pending EP3263584A4 (de) | 2015-02-27 | 2016-02-26 | Auf autophagische zellen gerichtete peptide und verwendung davon |
Country Status (4)
Country | Link |
---|---|
US (1) | US10421780B2 (de) |
EP (1) | EP3263584A4 (de) |
KR (1) | KR101844571B1 (de) |
WO (1) | WO2016137279A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019118527A1 (en) * | 2017-12-14 | 2019-06-20 | The Johns Hopkins University | Novel anti-fungal inhibitors |
KR102119197B1 (ko) * | 2018-04-23 | 2020-06-05 | 주식회사 엘베이스 | 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물 |
CN110330551B (zh) * | 2019-08-05 | 2023-02-28 | 中国医科大学 | 一种胰腺癌特异结合肽及其制备方法与用途 |
CN114848836B (zh) * | 2021-07-06 | 2023-09-15 | 中山大学孙逸仙纪念医院 | 一种偶联物及其在治疗内耳疾病上的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277613B1 (en) * | 1998-06-10 | 2001-08-21 | The Rockefeller University | TRF1 binding protein, methods of use thereof |
US20120042398A1 (en) * | 2008-10-13 | 2012-02-16 | San Diego State University (Sdsu) Foundation | Compositions for labeling and identifying autophagosomes and methods for making and using them |
EP2466294B1 (de) * | 2009-08-10 | 2014-07-23 | Japan Science And Technology Agency | Verfahren zur autophagiemessung |
KR20140130367A (ko) * | 2013-04-30 | 2014-11-10 | 경북대학교 산학협력단 | 히스톤 h1과 특이적으로 결합하는 펩타이드 및 이의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL217837B1 (pl) * | 2010-10-27 | 2014-08-29 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Rekombinowana molekuła DNA, kaseta ekspresyjna, wektor DNA, plazmid binarny, komórka roślinna, sposób otrzymywania polipeptydu w eukariotycznym gospodarzu oraz zastosowanie rekombinowanej molekuły DNA |
US9771393B2 (en) * | 2015-03-11 | 2017-09-26 | The United States Of America, As Represented By The Secretary Of Agriculture | Bioactive peptides having insecticide activity |
-
2016
- 2016-02-24 KR KR1020160022160A patent/KR101844571B1/ko active IP Right Grant
- 2016-02-26 EP EP16755929.3A patent/EP3263584A4/de active Pending
- 2016-02-26 WO PCT/KR2016/001943 patent/WO2016137279A1/ko active Application Filing
-
2017
- 2017-08-25 US US15/687,219 patent/US10421780B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277613B1 (en) * | 1998-06-10 | 2001-08-21 | The Rockefeller University | TRF1 binding protein, methods of use thereof |
US20120042398A1 (en) * | 2008-10-13 | 2012-02-16 | San Diego State University (Sdsu) Foundation | Compositions for labeling and identifying autophagosomes and methods for making and using them |
EP2466294B1 (de) * | 2009-08-10 | 2014-07-23 | Japan Science And Technology Agency | Verfahren zur autophagiemessung |
KR20140130367A (ko) * | 2013-04-30 | 2014-11-10 | 경북대학교 산학협력단 | 히스톤 h1과 특이적으로 결합하는 펩타이드 및 이의 용도 |
Non-Patent Citations (3)
Title |
---|
DERETIC ET AL: "Autophagy in innate and adaptive immunity", TRENDS IN IMMUNOLOGY, ELSEVIER LTD. * TRENDS JOURNALS, GB, vol. 26, no. 10, 1 October 2005 (2005-10-01), pages 523 - 528, XP027724237, ISSN: 1471-4906, [retrieved on 20051001] * |
OH J M ET AL: "The involvement of cellular prion protein in the autophagy pathway in neuronal cells", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 39, no. 2, 1 October 2008 (2008-10-01), pages 238 - 247, XP025434229, ISSN: 1044-7431, [retrieved on 20080712], DOI: 10.1016/J.MCN.2008.07.003 * |
See also references of WO2016137279A1 * |
Also Published As
Publication number | Publication date |
---|---|
US10421780B2 (en) | 2019-09-24 |
WO2016137279A1 (ko) | 2016-09-01 |
KR20160105329A (ko) | 2016-09-06 |
EP3263584A1 (de) | 2018-01-03 |
KR101844571B1 (ko) | 2018-05-14 |
US20180002380A1 (en) | 2018-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3302442A4 (de) | Darreichungsform und verwendung davon | |
EP3303379A4 (de) | Tigit-bindende wirkstoffe und verwendungen davon | |
EP3380125A4 (de) | Konjugate mit peptidgruppen und zugehörige verfahren | |
EP3253890A4 (de) | Tnfrsf-bindende wirkstoffe und verwendungen davon | |
EP3235830A4 (de) | Interleukin-15-proteinkomplex und verwendung davon | |
EP3197477A4 (de) | Peptidomimetische makrozyklen und formulierungen davon | |
EP3354661A4 (de) | Vollständig humaner antikörper gegen humanes cd137 und verwendung davon | |
EP3154594A4 (de) | Fap-aktivierte therapeutische mittel und damit verbundene verwendungen | |
EP3255059A4 (de) | Antimikrobielles peptid wy-21 und verwendung davon | |
EP3177638A4 (de) | Gerichtete peptide und verfahren zur verwendung | |
EP3096616A4 (de) | Antimikrobielle peptide vom dermaseptintyp und piscidintyp | |
EP3285805A4 (de) | Therapeutische antikörper und verwendungen davon | |
EP3191114A4 (de) | Occidiofungin-formulierungen und verwendungen davon | |
EP3265472A4 (de) | Zytotoxische hexim1-peptide und verwendungen davon | |
EP3145549A4 (de) | Topische formulierungen und verwendungen davon | |
EP3279209A4 (de) | Haftpeptid und verwendung dafür | |
EP3237374A4 (de) | Aminosäure- und peptidkonjugate und verwendungen davon | |
EP3199543A4 (de) | Neuartiges peptid und verwendung davon | |
EP3263584A4 (de) | Auf autophagische zellen gerichtete peptide und verwendung davon | |
EP3190129A4 (de) | Zentral wirkendes peptidderivat und pharmazeutische zusammensetzung | |
EP3378870A4 (de) | Neuartiges antimikrobielles peptid und verwendung davon | |
EP3223817A4 (de) | Im wesentlichen reines vemurafenib und dessen salze | |
EP3222630A4 (de) | Peptide zum targeting von kolorektalkrebs und medizinische verwendung davon | |
EP3302530A4 (de) | Auf cdh26 basierende therapeutika und deren verwendung | |
EP3336186A4 (de) | Depdc1-abgeleitetes peptid und impfstoff damit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170918 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180621 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 49/00 20060101ALI20180615BHEP Ipc: A61K 47/50 20170101ALI20180615BHEP Ipc: G01N 33/58 20060101ALI20180615BHEP Ipc: C07K 7/06 20060101AFI20180615BHEP Ipc: C07K 19/00 20060101ALI20180615BHEP Ipc: G01N 33/53 20060101ALI20180615BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220405 |